Abstract
Current stocks of the LCC15-MB cell line, which we originally isolated from a human breast-bone metastasis, were found to be genetically matched to the MDA-MB-435 cell line from the Lombardi Cancer Center (MDA-MB-435-LCC) using comparative genomic hybridisation, DNA microsatellite analysis and chromosomal number. LCC15-MB stocks used for our previously published studies as well as the earliest available LCC15-MB cells also showed identity to MDA-MB-435-LCC cells. The original karyotype reported for LCC15-MB cells was considerably different to that of MDA-MB-435 cells, indicating that the original LCC15-MB cells were lost to contamination by MDA-MB-435-LCC cells. Chromosome number is the simplest test to distinguish original LCC15-MB cells (n ∼ 75) from MDA-MB-435 (n ∼ 52). Collectively, our results prove that LCC15-MB cells currently available are MDA-MB-435 cells and we suggest their re-designation as MDA-MB-435-LCC15 cells. We also review the known misclassification of breast and prostate cancer cell lines to date and have initiated a register maintained at http//www.svi.edu.au/cell_lines_registry.doc.
Similar content being viewed by others
References
Sung V, Gilles C, Murray A et al. The LCC15-MB humanbreast cancer cell line expresses osteopontin and exhibits aninvasive and metastatic phenotype. Exp Cell Res 1998; 241(2): 273–84.
Thompson EW, Sung V, Lavigne M et al. LCC15-MB: A vi-mentin-positive human breast cancer cell line from a femoralbone metastasis. Clin Exp Metast 1999; 17(3): 193–204.
Clarke R, Leonessa F, Brunner N, Thompson EW. In vitromodels of human breast cancer. In Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia: Lippincott 1995.
Ackland ML, Newgreen D, Price JT et al. Epidermal growthfactor stimulates epithelio–mesenchymal transition in the stablehuman breast carcinoma cell line variant PMC42-LA. Lab Invest 2003; 83(3): 435–48.
Thompson EW, Paik S, Brunner N et al. Association ofincreased basement membrane invasiveness with absence ofestrogen receptor and expression of vimentin in human breastcancer cell lines. J Cell Physiol 1992; 150(3): 534–44.
Holst-Hansen C, Johannessen B, Hoyer-Hansen et al Uroki-nase-type plasminogen activation in three human breast cancercell lines correlates with their in vitro invasiveness. Clin ExpMetast 1996; 14(3): 297–307.
Cailleau R, Olive M, Cruciger QV. Long-term human breastcarcinoma cell lines of metastatic origin: Preliminary character-ization. In Vitro 1978; 14(11): 911–15.
Leonessa F, Green D, Licht T et al. MDA435/LCC6 andMDA435/LCC6MDR1: Ascites models of human breast cancer. Br J Cancer 1996; 73(2): 154–61.
Kallioniemi OP, Kallioniemi A, Piper J et al. Optimizing com-parative genomic hybridization for analysis of DNA sequencecopy number changes in solid tumors. Genes ChromosomesCancer 1994; 10(4): 231–43.
Allen DG, White DJ, Hutchins AM et al. Progressive geneticaberrations detected by comparative genomic hybridization insquamous cell cervical cancer. Br J Cancer 2000; 83(12): 1659–63.
Satya-Prakash KL, Pathak S, Hsu TC et al. Cytogenetic analy-sis on eight human breast tumor cell lines: high frequencies of1q, 11q and HeLa-like marker chromosomes. Cancer GenetCytogenet 1981; 3(1): 61–73.
Price JE, Fabra A, Zhang RD et al. Characterization of vari-ants of a human breast cancer cell line isolated from metastasesin different organs of nude mice. Int J Oncol 1994; 5: 459–67.
Bae SN, Arand G, Azzam H et al. Molecular and cellular anal-ysis of basement membrane invasion by human breast cancercells in matrigel-based in vitro assays. Breast Cancer Res Treat1993; 24(3): 241–55.
Markovic O, Markovic N. Cell cross-contamination in cell cultures: the silent and neglected danger. In Vitro Cell Dev BiolAnim 1998; 34(1): 1–8.
Walker JR. Identification and misidentification of the chromo-somes of heteroploid cell lines. J Natl Cancer Inst 1973; 51(4): 1113–5.
MacLeod RA, Dirks WG, Matsuo Y et al. Widespread intra-species cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999; 83(4): 555–63.
Rae JM, Cordero KE, Scheys JO et al. Genotyping for poly-morphic drug metabolizing enzymes from para. n-embeddedand immunohistochemically stained tumor samples. Pharmaco-genetics 2003; 13(8): 501–7.
Osborne CK, Hobbs K, Trent JM. Biological differences amongMCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 1987; 9(2): 111–21.
Scudiero DA, Monks A, Sausville EA. Cell line designationchange: multidrug-resistant cell line in the NCI anticancerscreen. J Natl Cancer Inst 1998; 90(11): 862.
Devarajan E, Chen J, Multani AS et al. Human breast cancerMCF-7 cell line contains inherently drug-resistant subcloneswith distinct genotypic and phenotypic features. Int J Oncol2002; 20(5): 913–20.
Gaffney EV. A cell line (HBL-100) established from human breast milk. Cell Tissue Res 1982; 227(3): 563–8.
Ross DT, Scherf U, Eisen MB et al. Systematic variation ingene expression patterns in human cancer cell lines. Nat Genet 2000; 24(3): 227–35.
Lee H, Lin EC, Liu L, Smith JW. Gene expression pro ling oftumor xenografts: In vivo analysis of organ-speci c metastasis. Int J Cancer 2003; 107(4): 528–34.
Ellison G, Klinowska T, Westwood RF et al. Further evidenceto support the melanocytic origin of MDA-MB-435. Mol Pathol 2002; 55(5): 294–9.
Jessani N, Liu Y, Humphrey M, Cravatt BF. Enzyme activitypro les of the secreted and membrane proteome that depictcancer cell invasiveness. Proc Natl Acad Sci USA 2002; 99(16): 10335–40.
Sellappan S, Grijalva R, Zhou X et al. Lineage in delity ofMDA-MB-435 cells: expression of melanocyte proteins in abreast cancer cell line. Cancer Res 2004; 64(10): 3479–85.
Stone KR, Mickey DD, Wunderli H et al. Isolation of a humanprostate carcinoma cell line (DU 145). Int J Cancer 1978; 21(3): 274–81.
Kaighn ME, Narayan KS, Ohnuki Y et al. Establishment andcharacterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17(1): 16–23.
Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP modelof human prostatic carcinoma. Cancer Res 1983; 43(4): 1809–18.
van Bokhoven A, Varella-Garcia M, Korch C et al. Widelyused prostate carcinoma cell lines share common origins. Prostate 2001; 47(1): 36–51.
van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cellsand are not of prostatic origin. Cancer Res 2001; 61(17): 6340–4.
O' Toole CM, Povey S, Hepburn P, Franks LM. Identity ofsome human bladder cancer cell lines. Nature 1983; 301(5899): 429–30.
Masters JR, Bedford P, Kearney A et al. Bladder cancer cellline cross-contamination: Identi cation using a locus-speci cminisatellite probe. Br J Cancer 1988; 57(3): 284–6.
Christensen B, Hansen C, Debiec-Rychter M et al. Identityof tumorigenic human urothelial cell lines and 'spontane-ously' transformed sublines. Br J Cancer 1993; 68(5): 879–84.
Nelson-Rees WA, Flandermeyer RR. HeLa cultures de ned. Science 1976; 191(4222): 96–8.
Webber MM, Horan PK, Bouldin TR. Present status of MA-160 cell line. Prostatic epithelium or HeLa cells. Invest Urol 1977; 14(5): 335–43.
Masters J. False cell lines. Int J Cancer 2002; 99(1): 154.
Drexler HG, Dirks WG, Matsuo Y, MacLeod RA. False leuke-mia–lymphoma cell lines: an update on over 500 cell lines. Leukemia 2003; 17(2): 416–26.
Barnes GL, Javed A, Waller SM, et al. Osteoblast-related tran-scription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63(10): 2631–7.
Kaplan J, Hukku B. Cell line characterization and authentication. Methods Cell Biol 1998; 57: 203–16.
UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer 2000; 82(9): 1495–509.
Rae JM, Ramus SJ, Waltham M et al. Common origins ofMDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metast 2004; 21(6): 543–52(this issue).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thompson, E.W., Waltham, M., Ramus, S.J. et al. LCC15-MB Cells are MDA-MB-435: A Review of Misidentified Breast and prostate cell lines. Clin Exp Metastasis 21, 535–541 (2004). https://doi.org/10.1007/s10585-004-4117-z
Issue Date:
DOI: https://doi.org/10.1007/s10585-004-4117-z